N/A N=246 Assessing Portal Hypertension With Methacetin Breath Test
Patients With Compensated Liver Cirrhosis
Primary: CSPH (Clinically Significant Portal Hypertension) — 81.82 percentage of agreement
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=178 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension
Liver Diseases · Portal Hypertension
Primary: Diagnostic Accuracy of SHAPE Liver Pressure Estimates (in dB) for Diagnosing Portal Hypertension With Catheter Pressure Measurements (in mmHg) as the Reference Standard…
N/A N=70 Velacur by Sonic Incytes for Portal Hypertension
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
N/A N=455 The Association With Peptic Ulcer Disease and Hepatic Vein Pressure Gradient
Cirrhosis · Chronic Liver Disease
Primary: The Association of HVPG and PUD in Patients With Liver Cirrhosis — 14.5; 15.3 mmHg
Phase 2 N=10 The Effect of Sorafenib on Portal Pressure
Clinically Significant Portal Hypertension
Primary: Patients With Change in HVPG From Baseline — 1; 1 participants
Phase 2 N=23 A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Liver Cirrhosis · Hepatic Cirrhosis · Portal Hypertension
Primary: Hepatic Venous Pressure Gradient (HVPG) — 15.2; 8.05; 20.62; 14.1 mmHg — p=0.257
Phase 2 N=30 Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients
Portal Hypertension · Liver Cirrhosis
Primary: Safety (Incidence and Severity of Adverse Events) — 23; 2 Number of adverse events
N/A N=49 Probiotics for Liver Cirrhosis With Portal Hypertension
Liver Cirrhosis · Portal Hypertension
Primary: Admission Due to Complications Related to Portal Hypertension — 2; 3 participants — p=0.25
N/A N=280 The SHUNT-V Study for Varices
Chronic Liver Disease
Primary: Disease Severity Index (DSI) Less Than/Equal to 18.3 to Rule Out Large Varices — 33; 3; 171; 68 Participants
Phase 4 N=29 Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
Ascites · Cirrhosis
Primary: Time to Recurrence of Ascites. — 10; 8 days — p=<0.05
Phase 4 N=64 Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
Liver Cirrhosis · Portal Vein Thrombosis
Primary: Recanalization Rate — 20; 11 Participants
Phase 3 N=30 Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Portopulmonary Hypertension
Primary: Change in Pulmonary Vascular Resistance — 7.1 percent difference from baseline
N/A N=48 Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
Hepatitis C, Chronic · Non-Alcoholic Fatty Liver Disease
Primary: Cholate Shunt Test — 28.0; 37.6; 33.4 SHUNT %
Phase 2 N=162 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Hypertension, Portal
Primary: Change in Portal Pressure at Year 1 (Change in HVPG From Baseline and 1 Year) — -0.39; -0.24; 0.19 mm HG — p=1.000
Phase 2 N=46 An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension
Compensated Cirrhosis and Portal Hypertension
Primary: Change From Baseline of the Blood Flow for the Total Renal Arteries (Study Part A (Serelaxin Treatment Group Only)) — 0.438 L/min
N/A N=343 Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
NASH - Nonalcoholic Steatohepatitis · Cirrhosis · Portal Hypertension
Primary: Number of Subjects With Matched Clinically Significant Portal Hypertension Based on Hepatic Venous Pressure Gradient (HVPG) and Methacetin Breath Test (MBT) — 190…
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Phase 4 N=106 PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
Liver Cirrhosis · Hypertension, Portal
Primary: Variceal Bleeding Events — 3; 3 Participants
N/A N=57 Regeneration of Liver: Portal Vein Embolization Versus Radiofrequency Assisted Ligation for Liver Hypertrophy (REBIRTH)
Liver Resection · Cancer
Primary: Changes in Liver Remnant Volume — 18.4; 80.7 percentage change
Phase 2 N=6 Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
Cirrhosis · Ascites Hepatic
Primary: Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites — 6; 4; 3; 0 Participants
N/A N=235 Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage
UGI Bleeding · Ulcer or Variceal Hemorrhage · Stigmata of Recent Hemorrhage
Primary: 30 Day Rebleeding Rate — 20; 8; 17; 6 Participants
N/A N=20 Effect of Intermittent Pedicle Clamping on Hepatocellular Injury During Liver Surgery
Hepatocellular Injury · Blood Loss
Primary: Hepatocellular Damage Reflected by Liver Fatty-acid Binding Protein (L-FABP) Levels — 9097; 11,688 ng*h/mL
N/A N=34 Transient Elastography in Autoimmune Hepatitis
Liver Cirrhosis
Primary: Sensitivity and Specifity of Transient Elastography in Detection of Liver Cirrhosis — 0.83; 1.00; 1.00; 0.97 Probability
Phase 2 N=263 Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
Cirrhosis · Portal Hypertension · Non-alcoholic Steatohepatitis
Primary: Mean Change in Hepatic Venous Pressure Gradient (HVPG) — -0.48; -0.81; -0.70; -0.18 mmHg
Phase 4 N=85 PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial
Portopulmonary Hypertension
Primary: Relative Change From Baseline to Week 12 in Pulmonary Vascular Resistance (PVR). — 0.63; 0.98 ratio — p=0.0001
N/A N=68 Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
N/A N=407 Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients
Cirrhosis of Liver
Primary: Detection Rate of Patients With HCC — 27.9; 86.0 percentage of HCC detected on each exam — p=<0.01
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Phase 3 N=20 Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)
Liver Disease
Primary: Results of HepQuant SHUNT Test: Elimination Rate (IV Phase 1 Only; Min-1) — 0.104; 0.092; 0.099 min-1
Phase 2 N=50 Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Hepatitis C · Cirrhosis · Portal Hypertension
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 72.0; 0; 71.4 percentage of participants